Shares of KALA BIO, Inc. (NASDAQ:KALA – Free Report) are going to reverse split on the morning of Monday, November 16th. The 1-30 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, November 15th.
KALA BIO Trading Down 5.8%
Shares of KALA stock traded down $0.01 during trading hours on Thursday, hitting $0.16. The stock had a trading volume of 381,307 shares, compared to its average volume of 223,330. KALA BIO has a one year low of $0.11 and a one year high of $95.50. The stock’s 50-day moving average price is $0.35 and its two-hundred day moving average price is $5.81.
KALA BIO (NASDAQ:KALA – Get Free Report) last posted its earnings results on Wednesday, August 19th. The company reported ($21.32) EPS for the quarter, missing analysts’ consensus estimates of ($6.00) by ($15.32).
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of KALA BIO in a research report on Monday, September 21st. Wall Street Zen upgraded KALA BIO from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, KALA BIO presently has a consensus rating of “Sell”.
View Our Latest Research Report on KALA
Hedge Funds Weigh In On KALA BIO
An institutional investor recently bought a new position in KALA BIO stock. BlackRock Inc. bought a new stake in KALA BIO, Inc. (NASDAQ:KALA – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 71,542 shares of the company’s stock, valued at approximately $124,000. BlackRock Inc. owned 0.37% of KALA BIO at the end of the most recent reporting period. Institutional investors and hedge funds own 24.61% of the company’s stock.
KALA BIO Company Profile
KALA BIO, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and severe eye diseases. The company is centered on its mesenchymal stem cell secretome platform, which is designed to deliver multiple naturally occurring growth factors and proteins that may support tissue repair and reduce inflammation. KALA BIO’s lead investigational product candidate, KPI-012, is being developed for the treatment of persistent corneal epithelial defects, a condition in which the surface of the cornea does not heal properly.
Further Reading
- Five stocks we like better than KALA BIO
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
